Interpace Diagnostics (IDXG) Reports European Patent Approval for Technology Underlying ThyraMIR® microRNA ... - StreetInsider.com

Interpace Diagnostics (IDXG) Reports European Patent Approval for Technology Underlying ThyraMIR® microRNA ... StreetInsider.com The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing ...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oTkUls
via IFTTT